lifestyle.thedishh.com

Author: Citius Oncology, Inc.

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma

March 4, 2026
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

February 13, 2026
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

February 12, 2026
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

December 23, 2025
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

December 11, 2025
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

December 9, 2025
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

December 5, 2025
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

October 20, 2025
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

October 16, 2025